HK1067316A1 - Method and composition for dry eye treatment - Google Patents

Method and composition for dry eye treatment

Info

Publication number
HK1067316A1
HK1067316A1 HK05100842.5A HK05100842A HK1067316A1 HK 1067316 A1 HK1067316 A1 HK 1067316A1 HK 05100842 A HK05100842 A HK 05100842A HK 1067316 A1 HK1067316 A1 HK 1067316A1
Authority
HK
Hong Kong
Prior art keywords
film
eye
composition
mixture
dry eye
Prior art date
Application number
HK05100842.5A
Other languages
English (en)
Inventor
Simon Benita
Gregory Lambert
Original Assignee
Yissum Res Dev Co
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Novagali Pharma Sa filed Critical Yissum Res Dev Co
Publication of HK1067316A1 publication Critical patent/HK1067316A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
HK05100842.5A 2001-11-01 2005-02-02 Method and composition for dry eye treatment HK1067316A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2001/001015 WO2003053405A1 (fr) 2001-11-01 2001-11-01 Procede et composition pour le traitement de l'oeil sec

Publications (1)

Publication Number Publication Date
HK1067316A1 true HK1067316A1 (en) 2005-04-08

Family

ID=11043109

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100842.5A HK1067316A1 (en) 2001-11-01 2005-02-02 Method and composition for dry eye treatment

Country Status (11)

Country Link
EP (1) EP1441696B1 (fr)
JP (1) JP2005513097A (fr)
CN (1) CN100335036C (fr)
AT (1) ATE468107T1 (fr)
AU (1) AU2002214233A1 (fr)
CA (1) CA2464243C (fr)
DE (1) DE60142187D1 (fr)
ES (1) ES2343512T3 (fr)
HK (1) HK1067316A1 (fr)
IL (1) IL161588A0 (fr)
WO (1) WO2003053405A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
EP1611879B1 (fr) * 2004-07-02 2009-08-12 Novagali Pharma SA Utilisation des émulsions pour injection intra- et périoculaire.
WO2006003519A2 (fr) * 2004-07-02 2006-01-12 Novagali Pharma Sa Utilisation d'emulsions pour des injections intra-oculaires et peri-oculaires
JP5272307B2 (ja) * 2004-07-16 2013-08-28 大正製薬株式会社 水性点眼剤
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
EP1929996B1 (fr) 2004-11-09 2011-02-16 Novagali Pharma S.A. Émulsions ophtalmiques contenant un agent immunosuppresseur
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US8288348B2 (en) 2005-07-13 2012-10-16 Allergan, Inc. Cyclosporin compositions
CA2625568C (fr) * 2005-10-10 2013-10-08 Novagali Pharma Sa Emulsions ophtalmiques contenant des prostaglandines
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
PL1834635T3 (pl) * 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
EP1864667B1 (fr) 2006-06-01 2013-09-04 Novagali Pharma S.A. Utilisation des promédicaments pour une administration oculaire intravitréenne
WO2008035246A2 (fr) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions contenant des composés ammonium quaternaire
CN101130058B (zh) * 2006-08-23 2011-10-05 华北制药集团新药研究开发有限责任公司 一种环孢菌素a眼用乳剂及其制备方法
WO2008120249A1 (fr) * 2007-03-30 2008-10-09 Sifi S.P.A. Produits pharmaceutiques à base de lipides polaires et non polaires pour utilisation ophtalmique
EP2228058A1 (fr) 2009-03-04 2010-09-15 Novagali Pharma S.A. Émulsion anionique d'huile dans l'eau contenant des prostaglandines et leurs utilisations
EP2308468A1 (fr) 2009-10-08 2011-04-13 Novaliq GmbH Nouvelle composition pharmaceutique comportant un médicament contre l'immunosuppression macrolide
EP2389939A1 (fr) 2010-05-28 2011-11-30 Novagali Pharma S.A. Utilisation de prostaglandines F2alpha et analogues pour la cicatrisation des lésions de la cornée et du conjonctif
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
CN109010270B (zh) * 2018-09-03 2021-07-30 辅必成（上海）医药科技有限公司 一种阳离子材料制备的眼用乳

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe

Also Published As

Publication number Publication date
CN100335036C (zh) 2007-09-05
DE60142187D1 (de) 2010-07-01
CN1558751A (zh) 2004-12-29
ES2343512T3 (es) 2010-08-03
IL161588A0 (en) 2004-09-27
WO2003053405A1 (fr) 2003-07-03
CA2464243A1 (fr) 2003-07-03
AU2002214233A1 (en) 2003-07-09
ATE468107T1 (de) 2010-06-15
CA2464243C (fr) 2010-01-19
EP1441696A1 (fr) 2004-08-04
JP2005513097A (ja) 2005-05-12
EP1441696B1 (fr) 2010-05-19

Similar Documents

Publication Publication Date Title
HK1067316A1 (en) Method and composition for dry eye treatment
AU655919B2 (en) Artificial tears
JP2005513097A5 (fr)
BR9915536A (pt) Composição e método para cuidados com o tecido
BR9610849A (pt) Composição de limpeza pessoal e processo para a inibiçao da perda de umidade pela pele e proteção da pele
ATE80290T1 (de) Loesung zur behandlung von ''dry-eye''erkrankungen.
HUP0001775A2 (hu) Testtisztító szer
GR3019478T3 (en) Dry eye treatment composition
WO2019030458A3 (fr) Emulsion moussante a haute teneur en huile et ses utilisations, notamment pour l'hygiene corporelle
BR0011883A (pt) Composição, produto para cabelos, produto para pele, e, processo de tratamento dos cabelos ou da pele
KR870002830A (ko) 고농도-오일-함유 무수 발포성 조성물
DE69704765D1 (de) Haarwaschmittel mit konditionierenden eigenschaften die bestimmte haarkonditionierende ester enthalten
TR199800437T1 (xx) Mikro em�lsiyonlar.
BR9711832A (pt) Composições lìquidas para a limpeza pessoal que contêm óleos e tensoativos sintéticos
BR0212867A (pt) Emulsão de água-em-óleo, composição, e, métodos para umectar pele de mamìfero, para desinfetar tecido de mamìfero e para suprir um agente farmacêutico a um mamìfero
AU2002224826A1 (en) Vesicle forming skin oil containing w/o-emulsifiers with a hydrophilic-lipophilic balance of 2-6, method for the production and use thereof
MX9803431A (es) Composicion cosmetica en emulsion de tres fases.
MA21492A1 (fr) Compositions en emulsions contenant des agents emulsionnants amphipathiques .
US4261061A (en) Process of treating athletic socks to prevent shoe irritation or blisters of the feet, and product
MXPA05003851A (es) Composicion cosmetica de tipo emulsion de agua en aceite que contiene una sal activa desodorante y un emulsor derivado de poliolefina que lleva al menos una parte polar.
GB2366203A (en) Absorbent tissues providing skin barrier enhancement
US5639450A (en) Cleansing and conditioning cosmetic composition
JP2010500459A5 (fr)
KR101308959B1 (ko) 저자극성 세안용 파우더 조성물
US6718914B2 (en) Method for neutralizing offensive chemical odors

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211031